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Poster Session I 91screened 12 OS and EWS cell lines for HER2 expression by FACS
analysis and analyzed the ability of HER2-T cells to 1) proliferate,
2) produce immunostimulatory cytokines, and 3) kill HER21 tu-
mor cells in cytoxicity assays upon exposure to HER21 OS and
EWS cell lines. The in vivo function was tested in amurine intraper-
itoneal xenograft model, which allows for serial imaging by biolu-
minescence with representative OS (LM7) and EWS (TC71) cell
lines. Imaging results were confirmed by pathological examination.
Results: 10 of 12 cell lines were HER21 by FACS analysis. HER2-
T cells recognized and killed all HER21OS and EWS cell lines in
cytotoxicity assays, whereas HER2-negative tumor cells were not
killed. Coculture ofHER2-T cells withHER21 tumor cell lines re-
sulted in T-cell proliferation, and secretion of IFN-g and IL-2 in
a HER2-dependent manner. In vivo, HER2-T cells eradicated es-
tablished intraperitoneal xenografts in 80% of animals harboring
LM7 and 70% of those harboring TC71 tumors, resulting in
long-term tumor free survival of treated animals. In contrast, deliv-
ery of non-transduced T cells did not change the tumor growth pat-
tern.Conclusions:This study shows that HER2 is a target antigen
for adoptive immunotherapy of OS and EWS. HER2-redirected T
cells not only recognized and killedHER21 tumor cells ex vivo, but
also eradicated experimental xenografts in vivo. Hence, adoptive
transfer of HER2-redirected T cells may represent a promising im-
munotherapeutic approach for OS and EWS.246
OPTIMIZING IMMUNOTHERAPY IMMEDIATELY AFTER HEMATOPOIETIC
STEM CELL TRANSPLANTATION (HSCT) TO EFFECTIVELY TREAT ESTAB-
LISHED NEUROBLASTOMA
Jing, W., Yan, X., Orentas, R.J., Johnson, B.D. Medical College of Wis-
consin, Milwaukee, WI.
Based on our previous success at inducing ‘‘protective’’ immunity
to neuroblastoma immediately after syngeneic HSCT using a com-
bination of adoptive immunotherapy and tumor vaccination, we hy-
pothesized that a similar immunotherapeutic approach would be
able to effectively treat mice with established tumors. Mice bearing
established AGN2a (neuroblastoma) tumors were given lethal total
body irradiation followed by HSCT consisting of bone marrow
supplemented with 6  106 T cells. On days 2, 7, and 14 after
HSCT, mice were vaccinated with irradiated AGN2a cells that
had been genetically modified to express CD54, CD80, CD86,
and CD137L. Bioluminescent imaging and caliper measurements
were used to monitor tumor growth. Our best results – delayed tu-
mor growth in all mice and 70% tumor-free survival – were seen
when mice were given HSCT, T cells derived from tumor-vacci-
nated syngeneic donors (pre-sensitized T cells), and vaccination.
Vaccination was an important component of the immunotherapy
in these mice, as only 36% of mice given pre-sensitized T cells
only (no vaccine) survived long-term. Several of the mice given
pre-sensitized T cells without vaccination had late tumor recur-
rences, which were not observed in vaccinated mice. This may re-
flect the requirement of a vaccine-based approach for the
induction or maintenance of long-term immune memory. Mice
givenHSCT, adoptive T cell transfer from naı¨ve mice, and vaccina-
tion also showed delayed tumor growth, but tumor-free survival was
lower (33%). Overall survival correlated with the frequency of IFN-
g-producing, tumor-reactive CD81 cells in lymphoid tissues of
treated mice. Moreover, we demonstrate that mice with regressing
tumors had higher frequencies of tumor-reactive T cells in their
lymphoid tissues thanmice with progressing tumors.When specific
immune cell subsets were depleted from the adoptively transferred
T cells two important observations were made. First, CD41 T cell
depletion was found to initially benefit tumor-bearing hosts, but the
generation of anti-tumor T cell memory was inhibited. Second,
more specific depletion of CD4 1 251 cells from the adoptively
transferred T cells can result in better tumor immunity without de-
creasing anti-tumorT cell memory. In summary, our results suggest
that a multi-faceted immunotherapeutic strategy including HSCT,
T cell adoptive transfer and early post-transplant tumor vaccination
can effectively treat mice with established neuroblastoma.247
HIGH-DOSE CHEMOTHERAPY WITH AUTOLOGOUS STEM-CELL SUP-
PORT VERSUS STANDARD-DOSE CHEMOTHERAPY FOR HIGH-RISK
BREAST CANCER: META-ANALYSIS OF INDIVIDUAL PATIENT DATA
FROM 15 RANDOMIZED ADJUVANT TRIALS
Ueno, N.T.1, Berry, D.A.1, Johnson, M.M.1, Lei, X.1, Lopez, V.T.1,
Caputo, J.A.1, Bregni, M.2, Demirer, T.2. 1The University of Texas
MD Anderson Cancer Center, Houston, TX; 2European Group for Blood
and Marrow Transplantation Meta-Analysis Group.
Background: The role of adjuvant high-dose chemotherapy
(HDC) with autologous hematopoietic stem-cell transplantation
for primary breast cancer at high risk of recurrence (at least 4 in-
volved axillary lymph nodes) remains ill-defined. Data from individ-
ual trials have limited power to show overall or subgroup benefit for
this indication. Methods: Individual patient data from 15 known
randomized trials (HDC vs standard-dose chemotherapy [SDC])
were merged into a single database. Disease-free survival (DFS)
was defined as time from surgery to recurrence or death; breast can-
cer-specific survival (BCSS) was time from surgery to death from
breast cancer or treatment-related toxicity; and overall survival
(OS) was time from surgery to death. Cox proportional hazards re-
gression was used to compare the effect of HDC vs SDC on DFS,
BCSS, and OS adjusted for age, trial, hormone receptor (HmR) sta-
tus (positive if either estrogen or progesterone receptor was posi-
tive), and menopausal (MP) status. Subgroup analyses were by
age, HmR and MP status. Results:Median follow-up for 6,210 pa-
tients (3,118HDC, 3,092 SDC) was 6 years (range, 0–15.3); median
patient age was 46 years (range, 20–67). HmR status was positive in
46.8% of patients, negative in 23.7%, and unknown in 29.5%;
68.9% were premenopausal, 29.4% were postmenopausal, and
1.7% was unknown.
After adjusting for age, trial andMP, HDCwas found to prolong
DFS (hazard ratio [HR] 0.87; 95% confidence interval [CI] 0.81–
0.94; P 5 0.0002) but not BCSS (HR 0.93; 95% CI 0.85–1.02; P
5 0.12) or OS (HR 0.95; 95%CI 0.87–1.03; P5 0.18). After adjust-
ing for HmR in the subset for which that information was available,
HDCwas found to prolong DFS (HR 0.83; 95%CI 0.77–0.90; P\
0.0001) and had modest but significant benefits on BCSS (HR 0.88;
CI 0.79–0.97; P5 0.014) andOS (HR 0.89; 95%CI 0.81–0.98; P5
0.016) compared to SDC. For BCSS and OS, none of age, MP or
HmR had a significant interaction with treatment, yet there was
a significant age by treatment interaction for DFS, in which HDC
was better for younger rather than older patients. Conclusions:
HDC as used in these 15 randomized studies prolongs DFS in ad-
juvant breast cancer. HDC has at most a modest benefit on BCSS
and OS compared to SDC. Whether HDC has benefit in the con-
text of contemporary taxane-based regimens and targeted therapies
is unknown and may be resolved by future clinical trials.248
KIR RECEPTOR-LIGAND INCOMPATIBILITY PREDICTS SUSCEPTIBILITY
OF OSTEOSARCOMA TO NK-MEDIATED LYSIS
Delgado, D.1, Hardin, H.2, Webster, D.2, DeSantes, K.1, Shaaban, A.2.
1University of Wisconsin School of Medicine & Public Health, Madison,
WI; 2University of Wisconsin School of Medicine & Public Health, Mad-
ison, WI.
Long-term survival for pediatric patients with high-risk solid tu-
mors remains poor despite multi-modality treatment, and new ap-
proaches are needed. Although the success of KIR (Killer
Immunoglobulin-Like Receptor) incompatible, haploidentical
stem cell transplantation has been suggested in hematological ma-
lignancies in adults and children, it has not been thoroughly exam-
ined for pediatric solid tumors. In this study, we evaluated the
potential for KIR-incompatible lysis of osteosarcoma cells, in vitro.
We hypothesized that the killing of osteosarcoma cell targets could
be predicted by the degree of KIR receptor/ligand mismatch. To
test this hypothesis, healthy donor NK cells were isolated and
KIR phenotype determined by flow cytometry. Consistent with pre-
vious studies, donorNK cells exhibited a high prevalence of all three
92 Poster Session Irelevant inhibitory KIRs (KIR2DL1, KIR2DL2/KIR2DL3,
KIR3DL1). Conversely, examination of three established osteosar-
coma cell lines (HOS, SaOS, and U2OS) demonstrated significant
variability in cell surface KIR ligand expression (HLA-C groups 1
and 2, HLA-Bw4) by flow cytometry and qRTPCR. Following
a 12-hour incubation of donor NK cells with IL-2, lysis of osteosar-
coma targets was measured in an annexin V flow cytometric assay.
Greater KIR receptor-ligand incompatibility was predictive of
higher killing of osteosarcoma cells. These findings were consistent
using NK effectors from different donors. Additionally, we ob-
served that at high passage number (.20), SaOS cells demonstrated
down-regulation of KIR ligand expression. These changes corre-
lated with increased lysis by the same donor NK cells. Our findings
suggest: 1) Variable expression of KIR ligands in osteosarcoma al-
lows potential susceptibility to KIR-incompatible, NK cell-medi-
ated lysis; 2) The killing of osteosarcoma cells by NK cells can be
predicted by the degree of receptor/ligandmismatch; and 3) During
expansion, osteosarcoma cells may down-regulate expression of
KIR ligands, resulting in increased susceptibility to lysis by KIR-in-
compatible NK cells. Further studies are needed to explore the util-
ity of KIR-incompatible, haploidentical stem cell transplantation
for patients with recurrent or metastatic osteosarcoma.249
PROLONGED SURVIVAL FOR ULTRA HIGH-RISK PEDIATRIC SARCOMA
PATIENTS FOLLOWING REDUCED-INTENSITY ALLOGENEIC STEM CELL
TRANSPLANTATION (ALLOSCT)
Baird, K.1, Love, C.1, Steinberg, S.M.3, Mackall, C.L.1, Wayne, A.S.1,
Fry, T.J.2. 1National Cancer Institute, NIH, Bethesda, MD; 2Children’s
National Medical Center, Washington, DC; 3National Cancer Institute,
NIH, Bethesda, MD.
Background: Pediatric sarcomas with ultra high-risk features
have overall survival rates of\20% and autologous transplantation
has not substantially improved outcome. AlloSCT can cure pediat-
ric hematologic malignancies, in part due to a graft versus tumor
(GVT) effect. The use ofmyeloablative alloSCT in sarcoma has his-
torically been limited by excessive toxicity.We piloted a reduced in-
tensity alloSCT (RISCT) regimen in pediatric sarcoma patients.
Methods: 18 patients with ultra-high risk features (Table) were
transplanted. Induction chemotherapy was administered for disease
control and targeted CD4 count reduction. Pre-transplant condi-
tioning consisted of cyclophosphamide 1,200 mg/m2/day  4, flu-
darabine 30 mg/m2/day  4 and melphalan 100 mg/m2  1.
Grafts were G-CSF mobilized unmodified peripheral blood stem
cells from 5–6/6 HLA-matched siblings. An initial cohort (n 5
13) received cyclosporine for GVHD prophylaxis and a second (n
5 5) received tacrolimus and sirolimus. Results: The regimen
was well tolerated with no transplant related mortality. All patients
had rapid engraftment and achieved full donor chimerism by post-
SCT day (D1) 28. Immune recovery was surprisingly brisk (median
CD41 count 309/mm3 D 1 28–42). 15/18 recipients developed
aGVHD: 13 grade 1–2 and 2 grade 3. 13/13 patients surviving .
100 days receiving cyclosporine as a single agent for GVHD pro-
phylaxis developed cGVHD whereas only 2/5 in the tacrolimus/si-
rolimus cohort have developed cGHVD. Median survival from
initial diagnosis is 35 months and from SCT is 13.9 months. Cur-
rently 6 patients are alive, 2 with no evidence of disease. Despite
early relapses, many patients experienced prolonged survival and
apparent improved responsiveness to chemotherapy, suggesting
a change in the natural history of these aggressive tumors following
alloSCT. Conclusions: Ultra high-risk sarcoma patients tolerated
RISCTwell and experienced brisk engraftment with kinetics similar
to myeloablative regimens. Alteration of GVHD prophylaxis ap-
pears to have decreased GVHD rates and severity. Median survival
compares favorably with outcomes in similarly ultra high-risk pa-
tients who did not undergo SCT. Given the rapid immune recovery
and favorable survival, this regimen appears to be a promising plat-
form for post-transplant immune-based therapy in pediatric sar-
coma patients.Patient Features
Number ofAge (yrs) DiagnosisUltra
high-risk
featuresprior
treatment
regimensDisease
status at
on-study/SCTDay 28–42
CD4
count/mm3Time to
relapse/PD
(days)Survival
post-SCT
(mos)20 RMS MR 5 PD/PR 253 100 34.019 RMS MR 3 PD/SD 442 42 4.310 EWS ER, MR 2 PD/SD 324 28 3.614 EWS ER, B/BM 3 PD/SD 335 100 5.818 RMS B/BM 2 PD/SD 443 100 14.521 EWS PD, B/BM 1 PD/SD 226 160 20.718 RMS MR 2 PD/SD 176 60 7.329 EWS B/BM 2 PD/SD 294 100 24.812 RMS MR 3 NED/NED 205 100 35.2*15 RMS B/BM 2 PD/SD 241 70 13.38 EWS B/BM 1 NED/NED 152 NED 8.9£19 EWS PD 1 PD/PD 481 42 32.2*25 EWS B/BM 2 PD/PD 148 100 14.925 DSRCT Metastatis§ 2 NED/NED 903 150 28.6*18 EWS B/BM 3 PD/PD 1003 38 4.415 EWS B/BM 1 NED/NED 171 NED 19.0*,£21 EWS B/BM 1 PD/PR 346 100 11.5*14 DSRCT Metastatic§ 2 NED/NED 463 NED 7.6*,£Median 17.8 Median 309 Median 13.9Key: RMS - rhabdomyosarcoma; EWS - Ewing sarcoma; DSRCT -
desmoplastic small round cell tumor; MR - multiply recurrent;
ER - early relapse within 1 year of diagnosis; B/BM - bone or
bone marrow metastasis at diagnosis; PD - progressive disease;
SD - stable disease; PR - partial response; NED - no evidence
of disease; mos - months; yrs - years
§Any metastatic site at diagnosis for DSRCT.
*Alive.
£No evidence of disease.250
LONG-TERM CLINICAL OUTCOME OF HIGH DOSE CHEMOTHERAPY
WITH AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION
(HDCT/ASCT) FOR BREAST CANCER PATIENTS
Jeong, S.H., Lee, H.W., Kang, S.Y., Park, J.S., Choi, J.H., Kim, H.C.
Ajou University School of Medicine, Suwon, Kyeong-Ki Do, Korea.
Background: Previous studies have shown that HDCT/ASCT
offer no survival advantage to standard treatment modality for
breast cancer in a short follow-up group. We have followed breast
cancer patients with HDCT/ASCT in a long-term follow up (me-
dian follow up 114.5months, ranges 79–142).Method:Forty-seven
consecutive patients who received HDCT/ASCT for treating
breast cancer at Ajou University Hospital between Dec. 1995 and
Mar. 2001 were reviewed retrospectively. Overall survival (OS),
progression free survival (PFS) and other clinical data were calcu-
lated according to the disease status at transplant. Student’s t-test
was done for statistics.Result:Themedian age was 43 years (ranges
27–59). Out of 47 patients, 11 were high risk for relapse, 9 were sen-
sitive relapse, 22 were refractory relapse and 5 were primary meta-
static disease before transplant. In high risk group, 6 patients were
stage IIIA, 5 were II with intensive lymph node infiltrations. Pa-
tients with primary metastatic cancer or refractory relapse showed
poor outcome (20% and 4.6% at 100 months, respectively). High
risk group maintained survival of 63.6% after 120 months whereas
sensitive relapse group showed 33.3% at 80 months. In high risk
group, TNM stage did not affect onOS or PFS, but ER/PR positive
group showed survival advantage over double negative group (p 5
0.0019), whereas C-erbB2 status did not affect the survival. Con-
clusion: Long-term follow up of clinical data suggests that
HDCT/ASCToffers as an alternative treatmentmodality for breast
cancer especially in case of high risk for relapse group with ER/PR
positive. Key Words: Breast Cancer, Myeloablative therapy, He-
matopoietic Stem Cell Transplantation.
